- Nemolizumab-ilto produced clinically meaningful reductions in itch and sleep disturbance as early as day 2 in atopic dermatitis and prurigo nodularis.
- Early itch response was associated with a higher likelihood of maintaining improvement through week 16.
- A significantly greater proportion of nemolizumab-treated patients achieved meaningful itch reduction versus placebo across pooled phase 3 trials.
- Targeting the interleukin-31 pathway directly addresses pruritus, a dominant and burdensome symptom in both conditions.
- Findings are from a post hoc analysis with nominal P values but support the clinical relevance of rapid itch control.
Source: Journal of the European Academy of Dermatology & Venereology
